CN103933570A - S1p受体调节剂的给药方案 - Google Patents

S1p受体调节剂的给药方案 Download PDF

Info

Publication number
CN103933570A
CN103933570A CN201410184034.0A CN201410184034A CN103933570A CN 103933570 A CN103933570 A CN 103933570A CN 201410184034 A CN201410184034 A CN 201410184034A CN 103933570 A CN103933570 A CN 103933570A
Authority
CN
China
Prior art keywords
agonist
receptor modulators
patient
purposes
fty720
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410184034.0A
Other languages
English (en)
Chinese (zh)
Inventor
C·博尔顿
P·比尔坦
O·大卫
A·德韦拉
T·迪莫捷
I·亨特
R·施穆德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43759693&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103933570(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN103933570A publication Critical patent/CN103933570A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/021—Measuring pressure in heart or blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/024—Measuring pulse rate or heart rate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
    • A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
    • A61B5/444—Evaluating skin marks, e.g. mole, nevi, tumour, scar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4833—Assessment of subject's compliance to treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Primary Health Care (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
CN201410184034.0A 2009-09-29 2010-09-20 S1p受体调节剂的给药方案 Pending CN103933570A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US24670609P 2009-09-29 2009-09-29
US61/246,706 2009-09-29
US25832909P 2009-11-05 2009-11-05
US61/258,329 2009-11-05
US30799210P 2010-02-25 2010-02-25
US61/307,992 2010-02-25
US35202910P 2010-06-07 2010-06-07
US61/352,029 2010-06-07

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2010800434886A Division CN102548579A (zh) 2009-09-29 2010-09-20 S1p受体调节剂的给药方案

Publications (1)

Publication Number Publication Date
CN103933570A true CN103933570A (zh) 2014-07-23

Family

ID=43759693

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201410184034.0A Pending CN103933570A (zh) 2009-09-29 2010-09-20 S1p受体调节剂的给药方案
CN2010800434886A Pending CN102548579A (zh) 2009-09-29 2010-09-20 S1p受体调节剂的给药方案

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010800434886A Pending CN102548579A (zh) 2009-09-29 2010-09-20 S1p受体调节剂的给药方案

Country Status (18)

Country Link
US (9) US20120264719A1 (https=)
EP (4) EP2482810A2 (https=)
JP (5) JP2013505983A (https=)
KR (1) KR20120083442A (https=)
CN (2) CN103933570A (https=)
AU (2) AU2010101513B4 (https=)
BR (1) BR112012006957A2 (https=)
CA (2) CA2773330C (https=)
IL (2) IL218486A0 (https=)
MA (1) MA33691B1 (https=)
MX (1) MX2012003740A (https=)
NZ (1) NZ598534A (https=)
PH (2) PH12012500520A1 (https=)
RU (1) RU2012117563A (https=)
SG (4) SG10201406168RA (https=)
TN (1) TN2012000104A1 (https=)
WO (1) WO2011041146A2 (https=)
ZA (2) ZA201201678B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116133665A (zh) * 2020-06-11 2023-05-16 纽约市哥伦比亚大学理事会 用于用鞘氨醇-1-磷酸受体调节剂芬戈莫德及其衍生物预防和治疗近视的方法和组合物

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2482810A2 (en) * 2009-09-29 2012-08-08 Novartis AG Dosage regimen of an s1p receptor modulator
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
BR112013017302B1 (pt) 2011-01-07 2021-12-07 Novartis Ag Composição farmacêutica em fase sólida
JP6133790B2 (ja) 2011-02-18 2017-05-24 ザ スクリプス リサーチ インスティテュート ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化
CN106344576A (zh) * 2011-10-12 2017-01-25 泰华制药工业有限公司 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症
PH12014500854A1 (en) * 2011-10-21 2021-08-09 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
HK1213636A1 (zh) 2013-04-04 2016-07-08 Novartis Ag 识别病患对投予s1p受体调节剂之反应
MX2016013245A (es) * 2014-04-10 2017-01-16 Novartis Ag Regimen de dosificacion de liberacion inmediata de moduladores s1p.
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
EP3716837B1 (en) 2017-11-30 2026-01-21 Viewmind, Inc. System and method for detecting neurological disorders and for measuring general cognitive performance
SG11202111417UA (en) * 2019-04-17 2021-11-29 Pear Therapeutics Inc Electronic devices and methods for treatment of depressive symptoms, depressive disorders utilizing digital therapies
WO2021158844A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
WO2021158843A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
WO2021158838A1 (en) 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor modulator
WO2021158845A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
WO2021158847A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
WO2021158841A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
WO2021158839A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
CA3262795A1 (en) * 2022-07-28 2024-02-01 Viewmind, Inc. Identifying disease-specific oculomotor patterns using visual stimuli, drug or treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101516345A (zh) * 2006-09-26 2009-08-26 诺瓦提斯公司 包含s1p调节剂的药物组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231560B1 (en) * 1999-02-10 2001-05-15 Baxter International Inc Method and apparatus for automatically controlling the level of medication
GB0211261D0 (en) * 2002-05-16 2002-06-26 Novartis Ag Organic compounds
PL372103A1 (en) 2002-05-16 2005-07-11 Novartis Ag Use of edg receptor binding agents in cancer
ES2294480T3 (es) * 2003-03-14 2008-04-01 Agi Therapeutics Research Limited Tratamiento de afecciones instestinales con n-2,3,3-tetrametilbiciclo(2.1.1)heptan-2-amina.
ES2558761T3 (es) 2003-05-19 2016-02-08 Novartis Ag Compuestos y composiciones inmunosupresores
WO2005025553A2 (en) 2003-09-12 2005-03-24 Neuronova Ab Treatment of disorders of nervous systemsystem with fty720
US7127355B2 (en) * 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
KR20140095109A (ko) 2004-11-29 2014-07-31 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
JP2007061274A (ja) * 2005-08-30 2007-03-15 Transcutaneous Technologies Inc センサからの副作用情報による投薬停止システムを備えたイオントフォレーシス装置
EP1905434A1 (en) 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
KR20110020928A (ko) 2008-06-20 2011-03-03 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
RS66784B9 (sr) 2008-12-22 2025-08-29 Novartis Ag Režim doziranјa agonista s1p receptora
EP2482810A2 (en) * 2009-09-29 2012-08-08 Novartis AG Dosage regimen of an s1p receptor modulator

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101516345A (zh) * 2006-09-26 2009-08-26 诺瓦提斯公司 包含s1p调节剂的药物组合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116133665A (zh) * 2020-06-11 2023-05-16 纽约市哥伦比亚大学理事会 用于用鞘氨醇-1-磷酸受体调节剂芬戈莫德及其衍生物预防和治疗近视的方法和组合物

Also Published As

Publication number Publication date
WO2011041146A3 (en) 2011-06-03
JP2020203892A (ja) 2020-12-24
RU2018118645A (ru) 2018-11-05
ZA201201678B (en) 2016-01-27
US20180263929A1 (en) 2018-09-20
PH12012500520A1 (en) 2012-10-22
US20260053756A1 (en) 2026-02-26
KR20120083442A (ko) 2012-07-25
SG10201913361RA (en) 2020-03-30
SG10201406168RA (en) 2014-11-27
EP3047848A1 (en) 2016-07-27
EP2482810A2 (en) 2012-08-08
JP2018172401A (ja) 2018-11-08
US20120264719A1 (en) 2012-10-18
NZ598534A (en) 2014-03-28
SG10201902152XA (en) 2019-04-29
MX2012003740A (es) 2012-04-30
US20140187516A1 (en) 2014-07-03
US20200222338A1 (en) 2020-07-16
SG178987A1 (en) 2012-04-27
JP7185426B2 (ja) 2022-12-07
EP3831371A1 (en) 2021-06-09
EP3061449A1 (en) 2016-08-31
BR112012006957A2 (pt) 2016-06-14
IL218486A0 (en) 2012-04-30
JP2016155840A (ja) 2016-09-01
US20160256416A1 (en) 2016-09-08
US20170304226A1 (en) 2017-10-26
MA33691B1 (fr) 2012-10-01
CN102548579A (zh) 2012-07-04
US10543179B2 (en) 2020-01-28
CA3129729A1 (en) 2011-04-07
ZA201404270B (en) 2014-12-23
US11759436B2 (en) 2023-09-19
TN2012000104A1 (en) 2013-09-19
AU2010101513A4 (en) 2014-06-26
PH12017501495A1 (en) 2018-07-02
IL250439A0 (en) 2017-03-30
CA2773330A1 (en) 2011-04-07
JP2013505983A (ja) 2013-02-21
AU2010101513B4 (en) 2016-05-05
RU2012117563A (ru) 2013-11-10
AU2010101513A6 (en) 2014-07-10
CA2773330C (en) 2021-11-02
JP2023093482A (ja) 2023-07-04
RU2018118645A3 (https=) 2021-09-13
US20180263930A1 (en) 2018-09-20
US20230086687A1 (en) 2023-03-23
WO2011041146A2 (en) 2011-04-07
AU2010300919A1 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
US11759436B2 (en) Dosage regimen of an S1P receptor modulator
AU2023204098A1 (en) Dosage regimen of an S1P receptor modulator
AU2015101631B4 (en) Dosage regimen of an S1P receptor modulator
HK40049428A (en) Dosage regimen of an s1p receptor modulator

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140723